Teratogen information service for pharmacists: A pilot study

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 18, Issue 2, 2011, Pages

  Tan, Michael Paul ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Drug information; Pharmacists; Pregnancy; Teratogens

Indexed keywords

AMANTADINE; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAHISTINE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CLOPIDOGREL; CYCLOBENZAPRINE; CYCLOPENTOLATE; DEXAMPHETAMINE; ESTROGEN; FLUCONAZOLE; HYDROQUINONE; IMIQUIMOD; ISOTRETINOIN; LEVONORGESTREL; LITHIUM; MELATONIN; MELOXICAM; METHYLPHENIDATE; MINOCYCLINE; MODAFINIL; NICOTINIC ACID; NITROFURANTOIN; PERINDOPRIL; QUINOLONE DERIVATIVE; RETINOL PALMITATE; TERATOGENIC AGENT; UNINDEXED DRUG;

ARTICLE; BREAST FEEDING; CLASSIFICATION; DRUG INFORMATION; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; PHARMACIST; PILOT STUDY; PREGNANCY; RISK; SATISFACTION; TELEPHONE; TERATOGENICITY;

BREAST FEEDING; CANADA; COUNSELING; DRUG INFORMATION SERVICES; FEMALE; HOTLINES; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PILOT PROJECTS; PREGNANCY; TERATOGENS;

EID: 79959823202     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66:207-214.
2. Pellerin P, Elefant E. Medication and pregnancy counseling, an incomfortable role for the retail pharmacists (article in French). Ann Pharm Fr 2004;62(11):253-259.
3. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001;95(1):127-131.
4. Pichereau J, Pathak A, Lacroix I, Montastruc JL, Damase-Michel C. Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. 27th French pharmacovigilance meeting, Montpellier. 10-12 April 2006. Fundamental Clin Pharmacol 2006;20:178 [Abstract 203].
5. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160(5 Pt 1):1190-1194.
6. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990;41(6):657-661.
7. De Santis M, Straface G, Cavaliere AF, Cinque B, Carducci B, Caruso A. Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol 2006:58(2):91-9.
8. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: Evaluation of perception risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health 2005;8(4):214-220.
9. Moretti ME, Koren G. Motherisk: The Toronto model for counseling in reproductive toxicology. In: Koren G, ed. Maternal-fetal toxicology - A clinician's guide. 3rd ed. Marcel Dekker, Inc. NY; 2001:767-88.
10. Briggs, GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Lippincott Williams & Wilkins, Philadelphia, PA; 2008.
11. Micromedex 1.0 Healthcare Series. Website. http://www.thomsonhc.com.myaccess.library.utoronto.ca/hcs/librarian/ND_T/HCS/CS/DE3D62/ND_PR/Main/DUPLICATIONSHIELDSYNC/8144E6/ND_PG/PRIH/ND_B/HCS/ND_P/Main/PFActionId/hcs.Home Accessed July 2010.
12. Hale TW. Medications and mothers' milk. A manual of lactational pharmacology. 13th ed. Hale Publishing, L.P. Amarillo, TX; 2008.
13. Garriguet D. Medication use among pregnant women. Health Rep 2006;17:9-18.
14. Irvine L, Flynn RWV, Libby G, et al. Drugs dispensed in primary care during pregnancy. A record-linkage analysis in Tayside, Scotland. Drug Saf 2010;33:593-604.
15. Wen SW, Yang T, Krewski D, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008;28:324-329.
16. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Parmacol 2008;64:1125-1132.
17. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006;15:537-545.
18. The Pharmacy Group. The Community Pharmacy 2010. The complete report on trends and insights in Canada. Rogers Publishing Ltd. Toronto; 2010.
19. Shoppers DrugMart. Drug Store Network- As of October 9, 2010. http://www.shoppersdrugmart.ca/english/corporate_information/investor_relations/corporate_overview/store_network/index.html Accessed on November 15, 2010.
20. Statistics Canada. Population and dwelling counts for Canada, provinces and territories 2006 and 2001 censuses. 2006. http://www12.statcan.ca/censusrecensement/2006/dp-pd/hlt/97-550/Index.cfm?TPL=P1C&age=RETR&LANG=Eng&T=101 Accessed on March 3, 2010.
21. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy. Drug Saf 2000; 23:245-53.
22. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-943.
23. Koren G, Sakaguchi S, Klieger C, et al. Toward improved pregnancy labeling. J Popul Ther Clin Pharmacol 2010;17:e349-57.